Hugo Ford

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

Hugo Ford, Andrea Marshall, John Bridgewater et al. · The Lancet Oncology · 2013 · 604 citations · Full text

Public Health, Community Health, Communities Of Practice +14

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study

Lucio Crinò, Federico Cappuzzo, Petr Zatloukal et al. · Journal of Clinical Oncology · 2008 · 217 citations

Medicine, Oncology, Pharmacology +14

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

John V. Reynolds, Shaun R. Preston, Brian Patrick O’Neill et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 173 citations · Full text

Medicine, Oncology, Perioperative Medicine +16

The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer

Ian Chau, Mark Allen, David Cunningham et al. · Journal of Clinical Oncology · 2004 · 156 citations

Medicine, Oncology, Surgery +17